Equibles does not estimate personal net worth.
Get an email with a short summary when Halozyme Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get HALO alertsDarren Snellgrove is recorded as CFO at Halozyme Therapeutics, Inc. (HALO) since June 8, 2026. Halozyme Therapeutics, Inc. reported in an 8-K filed April 30, 2026 that Darren Snellgrove was appointed Chief Financial Officer, effective June 8, 2026. Darren Snellgrove has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Halozyme Therapeutics, Inc. on November 5, 2026. Halozyme Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Halozyme Therapeutics, Inc. includes Helen Torley (CEO and Board Member), Elaine D. Sun (CFO), Nicole LaBrosse (CFO) and 7 others.
“On April 30, 2026, Halozyme Therapeutics, Inc. (the "Company") announced that Darren Snellgrove has been appointed to serve as the Company's Chief Financial Officer ("CFO"), effective June 8, 2026.”
“The third quarter was another exceptional quarter for Halerzyme. We delivered record royalty and total revenue, strong earnings growth, and substantial cash flow generation, while continuing to advance our future growth opportunities.”
“So 10 royalty bearing products is meaningfully different than one or two. And so that's what you're seeing in terms of our guidance beats and our raises. And you think about Darzalex is $4 billion in the quarter growing at 18%, VivGuard $1.5 billion, 60% growth rate.”
“So AI is definitely very much in action at Halozyme. Maybe I can give a few specific examples. First of all, we're using it for our scientific publications. We've been able to save about $50,000 per publication, do them about two to three times faster.”
“I am thrilled to be joining Halozyme at such an exciting point in the company's evolution. Over the past few months, I've had the opportunity to dive deeper into the business, and what has stood out to me is the strength of Halozyme's business model.”
2026-06-08–present
Biotechnology · Healthcare
CFO
2026-06-08–present
